Arcturus Therapeutics Holdings Inc (ARCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.23 Million) by net assets ($213.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arcturus Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Arcturus Therapeutics Holdings Inc carry for a breakdown of total debt and financial obligations.
Arcturus Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Immersion Corporation
NASDAQ:IMMR
|
-0.077x |
|
KNJ Co. Ltd
KQ:272110
|
0.065x |
|
BYC Co. Ltd
KO:001460
|
0.004x |
|
Mahanagar Telephone Nigam Limited
NSE:MTNL
|
0.004x |
|
Kuo Yang Construction Co Ltd
TW:2505
|
0.061x |
|
Kreditbanken A/S
CO:KRE
|
0.001x |
|
High Tide Inc
V:HITI
|
0.057x |
|
Gemini Space Station, Inc. Class A Common Stock
NASDAQ:GEMI
|
-0.255x |
Annual Cash Flow Conversion Efficiency for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Arcturus Therapeutics Holdings Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Arcturus Therapeutics Holdings Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $213.99 Million | $-74.27 Million | -0.347x | -39.99% |
| 2024-12-31 | $240.98 Million | $-59.75 Million | -0.248x | -281.53% |
| 2023-12-31 | $278.51 Million | $-18.10 Million | -0.065x | -154.91% |
| 2022-12-31 | $270.31 Million | $31.99 Million | 0.118x | +120.00% |
| 2021-12-31 | $228.21 Million | $-135.04 Million | -0.592x | -447.49% |
| 2020-12-31 | $396.55 Million | $-42.86 Million | -0.108x | +56.75% |
| 2019-12-31 | $25.79 Million | $-6.45 Million | -0.250x | +83.58% |
| 2018-12-31 | $13.64 Million | $-20.76 Million | -1.522x | -11079.72% |
| 2017-12-31 | $33.79 Million | $-460.00K | -0.014x | +96.66% |
| 2016-12-31 | $47.23 Million | $-19.24 Million | -0.407x | -55.64% |
| 2015-12-31 | $69.33 Million | $-18.15 Million | -0.262x | +81.57% |
| 2014-12-31 | $19.94 Million | $-28.33 Million | -1.420x | -840.49% |
| 2013-12-31 | $48.69 Million | $-7.35 Million | -0.151x | -105.40% |
| 2012-12-31 | $-567.00K | $-1.58 Million | 2.795x | +216.62% |
| 2011-12-31 | $985.00K | $-2.36 Million | -2.397x | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more